About: ACE2, the Receptor that Enables the Infection by SARS‐CoV‐2: Biochemistry, Structure, Allostery and Evaluation of the Potential Development of ACE2 Modulators

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: ACE2, the Receptor that Enables the Infection by SARS‐CoV‐2: Biochemistry, Structure, Allostery and Evaluation of the Potential Development of ACE2 Modulators Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	ACE2, the Receptor that Enables the Infection by SARS‐CoV‐2: Biochemistry, Structure, Allostery and Evaluation of the Potential Development of ACE2 Modulators
Creator	Zeuzem, Stefan Biondi, Ricardo Gross, Lissy Leroux, Alejandro Piiper, Albrecht Sacerdoti, Mariana
Source	Medline; PMC
abstract	Angiotensin Converting Enzyme 2 (ACE2) is the human receptor that interacts with the Spike protein of coronaviruses, including the one that produced the 2020 coronavirus pandemic (COVID‐19). Thus, ACE2 is a potential target for drugs that disrupt the interaction of human cells with SARS‐CoV‐2 to abolish infection. There is also interest on drugs that inhibit or activate ACE2, i.e. for cardiovascular disorders or colitis. Compounds binding at alternative sites could allosterically affect the interaction with Spike protein. We here review biochemical, chemical biology and structural information on ACE2, including the recent cryoEM structures of full length ACE2. We conclude that ACE2 is very dynamic and that allosteric drugs may be developed to target ACE2. At the time of the 2020 pandemic, we suggest that available ACE2 inhibitors or activators in advanced development should be tested for their ability to allosterically displace the interaction between ACE2 and the Spike protein.
has issue date	2020-07-14(xsd:dateTime)
bibo:doi	10.1002/cmdc.202000368
bibo:pmid	32663362
has license	no-cc
sha1sum (hex)	cece6b7d958bb1f275623c16f7cce75e95630c29
schema:url	https://doi.org/10.1002/cmdc.202000368
resource representing a document's title	ACE2, the Receptor that Enables the Infection by SARS‐CoV‐2: Biochemistry, Structure, Allostery and Evaluation of the Potential Development of ACE2 Modulators
has PubMed Central identifier	PMC7405163
has PubMed identifier	32663362
schema:publication	ChemMedChem
resource representing a document's body	covid:cece6b7d958bb1f275623c16f7cce75e95630c29#body_text
is schema:about of	named entity 'Spike' named entity 'advanced' named entity 'protein' named entity 'inhibitors' named entity 'human cells' named entity 'Converting' named entity 'protein' named entity 'DISRUPT' named entity 'ADVANCED' named entity 'SARS-COV-2' named entity 'SPIKE PROTEIN' named entity 'THEIR' named entity 'PROTEIN ' named entity 'IS A' named entity 'ACE2' named entity 'drugs' named entity 'inhibit' named entity 'ACE2' named entity 'coronavirus' named entity 'Compounds' named entity 'ACE2' named entity 'biochemical' named entity 'tested' named entity 'Thus' named entity 'Angiotensin Converting Enzyme 2' named entity 'infection' named entity 'allosterically' named entity 'allosteric' named entity 'ACE2' named entity 'receptor' named entity 'coronaviruses' named entity 'ACE2' named entity 'disrupt' named entity 'Angiotensin II' named entity 'hepatology' named entity 'substrate' named entity 'ACE2' named entity 'esterification' named entity 'lung' named entity 'Angiotensin II' named entity 'diabetology' named entity 'ACE2' named entity 'RBD' named entity 'extracellular' named entity 'interact' named entity 'hypertension' named entity 'Dimers' named entity 'helix' named entity 'viral protein' named entity 'physiological' named entity 'Spike protein' named entity 'biochemist' named entity 'SARS-CoV-1' named entity 'extracellular' named entity 'ACE2' named entity 'University of Buenos Aires' named entity 'chemical biology' named entity 'ACE2' named entity 'active site' named entity 'dimers' named entity 'ACE2' named entity 'active site' named entity 'dimer' named entity 'allosteric' named entity 'crystallographer' named entity 'infectivity' named entity 'ACE2' named entity 'PhD' named entity 'ACE2' named entity 'H34' named entity 'approved drug' named entity 'colitis' named entity 'allostery' named entity 'amino acid' named entity 'substrate' named entity 'anti-viral'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software